Efficacy and Safety ofSanGrow Decoction for Patients With Diabetes

SanGrow Decoction in Patients With Diabetes- Single Center, Open, and Non-randomized Study

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02660593

Enrollment

Registered

2016-01-21

Start date

2016-03-31

Completion date

2017-07-31

Last updated

2016-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus

Keywords

Diabetes Mellitus, Chinese medicine, exercise, diet

Brief summary

MedlinePlus related topics: Blood Sugar Primary Outcome Measures: * Fast glucose and HbA1c change between the baseline and end of study \[ Time Frame: From baseline to 30 and 100 days\] * \[ Designated as safety issue: No \] * Successful rate of blood glucose control (the proportion of patients with HbA1c \<7%) \[ Time Frame: From baseline to 30 days and 100 days\] \[ Designated as safety issue: No \] Secondary Outcome Measures: • To evaluate the change of quality of life in the 1 months by the health questionnaire SF-36 \[ Time Frame: From baseline to month 1 \] \[ Designated as safety issue: No \]

Detailed description

This study is aimed to evaluate the safety and efficacy of Sangrow Decotion, diet and exercise for the treatment of type 2 diabetes. Previous study has shown that this therapeutic regimen is safe and effective.

Interventions

DIETARY_SUPPLEMENTSanGrow Decoction

SanGrow Decoction is perpared according to the principle of Chinese medicine to treat thirsty and maransis.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

10 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Type II diabetes mellitus patients who have received medical treatment for more than 3 months * Patients willing to sign written informed consent form

Exclusion criteria

* Patients unable or unwilling to comply with the requirements of the protocol * Females who are pregnant or nursing or females of childbearing potential who are unwilling to maintain contraceptive therapy for the duration of the study * Life expectancy \< 6 months due to concomitant illnesses.

Design outcomes

Primary

Measure	Time frame	Description
Blood Sugar level	From baseline to 30 and 90 days	Fast glucose change between the baseline and end of study

Countries

China

Contacts

Primary ContactShizhan Chi, PhD

chishizhan@lawyee.net86-10-53109996

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026